Mirna Therapeutics, a globally renowned biotechnology company with a far-reaching record in the research and development of microRNA (miRNA) technology has hired Dr. Clay Siegall PhD to its Board of Directors. Dr. Siegall has numerous experience in the pharmaceutical industry and will play major roles in leading the company and its products to the best direction, and that will only be up. Mirna Therapeutics is focused on the development and manufacturing of miRNA therapeutics and has developed several patents by their scientists with numerous applications to the biology of cancer and similar oncogenic diseases.
MiRNA is used in a variety of applied biomedical fields, but have a strong potential for cancer research and studies. Being 20-25 nucleotides long, these biochemical are able to affect gene expression at a global genomic level by interacting and interfering with messenger RNAs. Naturally, they are naturally used by the body as regulators for when genes express certain gene sequences and in turn, adjusting multiple pathways within an individual cell. MiRNA plays an essential biological role in not only the expression of multiple genes, but also in embryonic development, inflammation, and immunity which all play an essential role in the proliferation of cancer cells. Further research and development of miRNAs into pharmaceuticals can provide landslide genetic treatment for multiple types of human cancers.
Dr. Siegall was educated in zoology as an undergraduate and genetics as a graduate from two prestigious University on the Atlantic coast of the United States. From there and beyond, Siegall progressed in a strong track record of over 70 academic publications and 15 patents. Furthermore, Siegall had a strong record of leadership as Director, President, and CEO of large biopharmaceutical companies such as Ultragenyx Pharmaceutical and Seattle Genetics. Siegall also led Seattle Genetics to create and distribute a diverse range of antibody-based cancer treatment therapies, some had the rare opportunity to be granted accelerated approval for manufacturing by the US Food and Drug Administration. Siegall has also capitalized his companies by securing over one billion dollars’ worth of public and private funding through his perseverance and his directive inspiration.